• Je něco špatně v tomto záznamu ?

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

M. Gavriatopoulou, P. Musto, J. Caers, G. Merlini, E. Kastritis, N. van de Donk, F. Gay, U. Hegenbart, R. Hajek, S. Zweegman, B. Bruno, C. Straka, MA. Dimopoulos, H. Einsele, M. Boccadoro, P. Sonneveld, M. Engelhardt, E. Terpos,

. 2018 ; 32 (9) : 1883-1898. [pub] 20180723

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028311
E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 30038381
DOI 10.1038/s41375-018-0209-7
Knihovny.cz E-zdroje

The introduction of novel agents in the management of multiple myeloma and related plasma cell dyscrasias has changed our treatment approaches and subsequently the outcome of patients. Due to current advances, the European Myeloma Network updated the diagnostic and therapeutic recommendations for patients with Waldenström's macroglobulinemia (WM), AL-amyloidosis, monoclonal immunoglobulin deposition disease (MIDD), POEMS syndrome, and primary plasma cell leukemia. For patients with WM, the combination of rituximab with chemotherapy remains the treatment cornerstone, while the Bruton-tyrosine kinase inhibitor ibrutinib has been introduced and approved for relapsed/refractory disease. The management of light chain amyloidosis depends on the presence and severity of heart disfunction. If present, intensification with an autologous stem cell transplantation (ASCT) is not recommended. Further aggregation of misfolded light chains could be prevented by doxycycline or monoclonal antibodies targeting amyloid deposits. Initial treatment generally consists of melphalan/dexamethasone or bortezomib-based regimens. For relapsing patients, one can consider proteasome inhibitors, immunomodulatory agents, melphalan or daratumumab. Because intact or light-chain immunoglobulins are also the culprits for MIDD, the small monoclonal plasma cells' clones should be treated and generally respond well to bortezomib-based treatment. POEMS syndrome is a well-defined clinical entity that can present as solitary bone lesions or disseminated disease. Radiation therapy is used for patients with localized disease and result in long-lasting response. Systemic treatment should be proposed to patients with disseminated disease, but regimens that can worsen a pre-existing polyneuropathy should be avoided. PPCL is located at the other end of the spectrum of plasma cell disorders and is associated with an aggressive disease course and poor prognosis. It requires an imminent, multi-phase and novel agents-based therapy, including induction, ASCT, consolidation and maintenance, with short treatment-free intervals. Patients not eligible for transplant procedures require personalized, intensive therapeutic approach. Allogeneic stem cell transplantation can be used in selected patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028311
003      
CZ-PrNML
005      
20190815105430.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-018-0209-7 $2 doi
035    __
$a (PubMed)30038381
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gavriatopoulou, Maria $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
245    10
$a European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias / $c M. Gavriatopoulou, P. Musto, J. Caers, G. Merlini, E. Kastritis, N. van de Donk, F. Gay, U. Hegenbart, R. Hajek, S. Zweegman, B. Bruno, C. Straka, MA. Dimopoulos, H. Einsele, M. Boccadoro, P. Sonneveld, M. Engelhardt, E. Terpos,
520    9_
$a The introduction of novel agents in the management of multiple myeloma and related plasma cell dyscrasias has changed our treatment approaches and subsequently the outcome of patients. Due to current advances, the European Myeloma Network updated the diagnostic and therapeutic recommendations for patients with Waldenström's macroglobulinemia (WM), AL-amyloidosis, monoclonal immunoglobulin deposition disease (MIDD), POEMS syndrome, and primary plasma cell leukemia. For patients with WM, the combination of rituximab with chemotherapy remains the treatment cornerstone, while the Bruton-tyrosine kinase inhibitor ibrutinib has been introduced and approved for relapsed/refractory disease. The management of light chain amyloidosis depends on the presence and severity of heart disfunction. If present, intensification with an autologous stem cell transplantation (ASCT) is not recommended. Further aggregation of misfolded light chains could be prevented by doxycycline or monoclonal antibodies targeting amyloid deposits. Initial treatment generally consists of melphalan/dexamethasone or bortezomib-based regimens. For relapsing patients, one can consider proteasome inhibitors, immunomodulatory agents, melphalan or daratumumab. Because intact or light-chain immunoglobulins are also the culprits for MIDD, the small monoclonal plasma cells' clones should be treated and generally respond well to bortezomib-based treatment. POEMS syndrome is a well-defined clinical entity that can present as solitary bone lesions or disseminated disease. Radiation therapy is used for patients with localized disease and result in long-lasting response. Systemic treatment should be proposed to patients with disseminated disease, but regimens that can worsen a pre-existing polyneuropathy should be avoided. PPCL is located at the other end of the spectrum of plasma cell disorders and is associated with an aggressive disease course and poor prognosis. It requires an imminent, multi-phase and novel agents-based therapy, including induction, ASCT, consolidation and maintenance, with short treatment-free intervals. Patients not eligible for transplant procedures require personalized, intensive therapeutic approach. Allogeneic stem cell transplantation can be used in selected patients.
650    _2
$a management nemoci $7 D019468
650    _2
$a lidé $7 D006801
650    _2
$a plazmocelulární leukemie $x diagnóza $x terapie $7 D007952
650    _2
$a nádory plazmocelulární $x diagnóza $x terapie $7 D054219
650    _2
$a paraproteinemie $x diagnóza $x terapie $7 D010265
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Musto, Pellegrino $u Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilacata, Rionero in Vulture (Pz), Vulture, Italy.
700    1_
$a Caers, Jo $u Department of Hematology, University Hospital of Liege, Liege, Belgium.
700    1_
$a Merlini, Giampaolo $u Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo', University of Pavia, Pavia, Italy.
700    1_
$a Kastritis, Efstathios $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
700    1_
$a van de Donk, Niels $u Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Gay, Francesca $u Division of Hematology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy.
700    1_
$a Hegenbart, Ute $u Department of Internal Medicine V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany.
700    1_
$a Hajek, Roman $u Department of HematoOncology, University Hospital Ostrava and Faculty of Medicine OU, Ostrava, Czech Republic.
700    1_
$a Zweegman, Sonja $u Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Bruno, Benedetto $u Division of Hematology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy.
700    1_
$a Straka, Christian $u Department of Hematology & Oncology, Schön Klinik Starnberger See, Berg, Germany.
700    1_
$a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
700    1_
$a Einsele, Hermann $u Department of Internal Medicine II, University Hospital Würburg, Würzburg, Germany.
700    1_
$a Boccadoro, Mario $u Division of Hematology, S. Giovanni Battista Hospital, University of Turin, Turin, Italy.
700    1_
$a Sonneveld, Pieter $u Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
700    1_
$a Engelhardt, Monika $u Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
700    1_
$a Terpos, Evangelos $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. eterpos@med.uoa.gr.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 32, č. 9 (2018), s. 1883-1898
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30038381 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190815105658 $b ABA008
999    __
$a ok $b bmc $g 1433460 $s 1066771
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 32 $c 9 $d 1883-1898 $e 20180723 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace